Home / Dermatitis / Sonoma Pharmaceuticals Launches Loyon

Sonoma Pharmaceuticals Launches Loyon

Sonoma Pharmaceuticals, Inc. has begun US commercialization of the company’s new Loyon® product. Under the supervision of a healthcare practitioner, Loyon is intended to manage and relieve the scaling, erythema, and itching associated with various types of dermatoses including seborrhea and seborrheic dermatitis.

Loyon is a unique, patented combination of the dry emollient Cetiol® CC and the medical silicone oil dimethicone. The liquid compound is easily applied, absorbs quickly and spreads exceptionally well due to its low surface tension, the company says. The product received a new 510(k) clearance from the FDA in March 2017.

“Chronic inflammatory skin diseases are commonly characterized by well-defined areas of erythematous plaques and scales.  It is estimated that 25% of the general population has seborrheic dermatitis and up to 8.5% have psoriasis with the presence of scaling. Many patients can feel stigmatized and suffer from marked physical and psychological disease burden, contributing to significant reduction of quality of life,” says Dr. Arnd Jacobi, M.D. and assistant professor at the University Medical Center Hamburg-Eppendorf, Germany.  “Providing a fast and effective treatment that will help improve the scaling can only help with this burden and enhance the overall treatment outcome.”

Sonoma Pharmaceutical’s dermatology division’s 30-person sales team is currently introducing Loyon to US dermatologists. More information is available online.

About Dr. J. Kim

Dr Kim developed (and is continuing to develop) dermatology research news as we way from dermatologists to stay on top of the latest advances in the field of dermatology.

Check Also

Golimumab dermatology

FDA Approves Jansen’s Golimumab for PsA, AS

The U.S. Food and Drug Administration (FDA) approved Jansen’s SIMPONI ARIA® (golimumab) for the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Simponi is the only fully-human anti-tumor necrosis factor (TNF)-alpha therapy administered via a 30-minute infusion.The new approvals follow the first FDA approval of SIMPONI ARIA® in 2013 for the treatment of moderately …

Leave a Reply

Your email address will not be published. Required fields are marked *